PARG-IN-4
Product Specifications
UNSPSC Description
PARG-IN-4 (Formula (A)) is an orally active and cell-permeable PARG inhibitor. PARG-IN-4 effectively inhibits tumor growth in mouse models. PARG-IN-4 can be used in cancer research[1].
Target Antigen
Poly(ADP-ribose) Glycohydrolase (PARG)
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/parg-in-4.html
Solubility
DMSO : 20 mg/mL (ultrasonic;warming;heat to 80°C)
Smiles
CC1(CC1)NS(=O)(C2=CC(N3C[C@@H](N[C@H](C3)C)C)=C(C=NN4C5=NN=C(C(F)F)S5)C4=C2)=O
Molecular Weight
497.59
References & Citations
[1]Paul A Barsanti, et al. Piperazine substituted indazole compounds as inhibitors of parg. Patent WO2023183850A1.
Shipping Conditions
Room Temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-156881/PARG-IN-4-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-156881/PARG-IN-4-SDS-MedChemExpress.pdf
Clinical Information
Phase 4
CAS Number
2988890-20-4
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1221173-01 0.02 mg (E-Coli)
Recombinant Burkholderia phytofirmans GTPase obg (obg)
Ask
View Details MBS1221173-02 0.02 mg (Yeast)
Recombinant Burkholderia phytofirmans GTPase obg (obg)
Ask
View Details MBS1221173-03 0.1 mg (E-Coli)
Recombinant Burkholderia phytofirmans GTPase obg (obg)
Ask
View Details